Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Survival of Hemodialysis-Dependent Multiple Myeloma Patients and Factors Associated with Dialysis Independence: A Real-World Study in China

Chenyun Wang, Jinuo Wang, Yang Yang, Donghua He, Gaofeng Zheng, Xiaoyan Han, Jingsong He, Jinping Ying, Wenjun Wu, Zhen Cai

Blood (2024) 144 (Supplement 1): 6913.

https://doi.org/10.1182/blood-2024-201472

Published: 2024

Journal Articles

Selinexor Combined with Daratumumab, Thalidomide, and Dexamethasone in Patients with First Relapsed Multiple Myeloma: A Single-Arm, Multicenter, Prospective Study

Qingxiao Chen, Jiasheng Wang, Yang Yang, Gaofeng Zheng, Jing Chen, Xiaoyan Han, Li Yang, Wenjun Wu, YI LI, Donghua He, Jingsong He, Zhen Cai

Blood (2024) 144 (Supplement 1): 7051.

https://doi.org/10.1182/blood-2024-197887

Published: 2024

Journal Articles

The Efficacy of Roxadustat in Multiple Myeloma Patients with Renal Insufficiency and Anemia: A Real-World Study

Shuchan Li, Xiaoyan Han, Gaofeng Zheng, Jingsong He, Wenjun Wu, Yang Yang, Qingxiao Chen, Donghua He, Mengmeng Dong, Jinuo Wang, Yi Li, Li Yang, Zhen Cai

Blood (2023) 142 (Supplement 1): 4726.

https://doi.org/10.1182/blood-2023-184617

Published: 2023

Journal Articles

Increase of Dnts Correlated with Clinic Outcome after Allogeneic DNT Cells Infusion in r/r AML Patients

Huiyao Gu, Donghua He, Xiaofeng Han, Yi Li, Li Yang, Enfan Zhang, Haicun Xie, Yu Cheng, Fuqiang Wu, Guangrong Song, Daqing Liu, Liming Yang, Jingsong He, Zhen Cai

Blood (2023) 142 (Supplement 1): 6867.

https://doi.org/10.1182/blood-2023-186221

Published: 2023

Journal Articles

Real-World Clinical Outcomes of Pomalidomide-Based and Daratumumab-Based Therapies in Patients with Relapsed/Refractory Multiple Myeloma: A Single-Center Retrospective Cohort Study

Xiaoyan Han, Xincheng Jiang, Jingsong He, Gaofeng Zheng, Yaqin Xiong, Yanling Wen, Yang Yang, Donghua He, Qingxiao Chen, Wenjun Wu, Yi Zhao, Yi Li, Zhen Cai

Blood (2023) 142 (Supplement 1): 6639.

https://doi.org/10.1182/blood-2023-184794

Published: 2023

Journal Articles

Preliminary Outcomes of Orelabrutinib Plus R-CHOP in Treatment-Naive Patients with Double-Expression Diffuse Large B-Cell Lymphoma

Yang Yang, Jingsong He, Yi Zhao, Wenjun Wu, Gaofeng Zheng, Xiaoyan Han, Donghua He, Tao Cheng, Zhen Cai

Blood (2023) 142 (Supplement 1): 6222.

https://doi.org/10.1182/blood-2023-187906

Published: 2023

Journal Articles

A Prospective Phase II Clinical Study of Low-Frequency Daratumumab for the Treatment of Systemic Light Chain Amyloidosis

Donghua He, Xinyi Meng, Jingsong He, Wenjun Wu, Jinuo Wang, Chunting Zhu, Xiaoyan Han, Yi Zhao, Gaofeng Zheng, Yi Li, Xing Guo, Qingxiao Chen, Fangshu Guan, Zhen Cai

Blood (2023) 142 (Supplement 1): 3400.

https://doi.org/10.1182/blood-2023-184689

Published: 2023

Journal Articles

When Patients with Plasma Cell Disorders Encountered the Largest Omicron Wave (December 2022) in China: A Real-World Multicenter and Multiregional Study

Xincheng Jiang, Zhen Cai, Xiaoyan Han, Fengyan Jin, Gang An, Jian Hou, Jingsong He, Qingming Wang, Wenjun Wu, Yi Zhao, Songfu Jiang, Shuchan Li, Zhenshu Xu, Gaofeng Zheng, Yang Yang, Qingxiao Chen, Donghua He, Yi Li

Blood (2023) 142 (Supplement 1): 6673.

https://doi.org/10.1182/blood-2023-174224

Published: 2023

Journal Articles

Analysis of Clinical Characteristics and High-Risk Factors of Patients with Extramedullary Relapse Multiple Myeloma

XiaoYan Yue, GaoFeng Zheng, Donghua He, Yang Yang, Xiaoyan Han, Yi LI, Yi Zhao, Qingxiao Chen, WenJun Wu, He Huang, Zhen Cai, Jingsong He

Blood (2022) 140 (Supplement 1): 7197.

https://doi.org/10.1182/blood-2022-159859

Published: 2022

Journal Articles

The Efficacy of Residual Plerixafor of Second-Day Stem Cell Mobilization in Multiple Myeloma Patients

Donghua He, Chunting Zhu, Xing Guo, Xin Huang, Xiaoyan Han, GaoFeng Zheng, Yi Zhao, Yang Yang, Wenjun Wu, Jimei Ge, Enfan Zhang, He Huang, Jingsong He, Zhen Cai

Blood (2022) 140 (Supplement 1): 12813–12814.

https://doi.org/10.1182/blood-2022-166394

Published: 2022

Journal Articles

Preliminary Outcomes of Orelabrutinib Plus RCHOP in Treatment-Naïve Patients with Double-Expression Diffuse Large B Cell Lymphoma

Yang Yang, Jingsong He, Yi Zhao, Wenjun Wu, GaoFeng Zheng, Xiaoyan Han, Donghua He, He Huang, Zhen Cai

Blood (2022) 140 (Supplement 1): 12102–12103.

https://doi.org/10.1182/blood-2022-168017

Published: 2022

Journal Articles

Efficacy and Safety of Chidamide Combined with Thalidomide, Cyclophosphamide, and Dexamethasone (TC2D) As a Novel Oral Quadruplet Regimen for the Treatment of Relapsed/Refractory Multiple Myeloma: Initial Results of a Phase IIa, Multicenter Clinical Trial

Yi Li, Jingsong He, Xiaoyan Han, Gaofeng Zheng, Enfan Zhang, Qingxiao Chen, Donghua He, Yi Zhao, Jiaping Fu, Lihong Shou, Wenhua Jiang, Wei Jiang, Shenxian Qian, Huixian Hu, He Huang, Zhen Cai

Blood (2021) 138 (Supplement 1): 4761.

https://doi.org/10.1182/blood-2021-149188

Published: 2021

Journal Articles

Multiple Myeloma Cell-Derived Interleukin-32gamma Increases the Immunosuppressive Function of Macrophages By Promoting Indoleamine 2,3-Dioxygenase (IDO) Expression

Haimeng Yan, Donghua He, Xi Huang, MD, Zhang En Fan, He Huang, MD, Zhen Cai, MD PhD

Blood (2018) 132 (Supplement 1): 3179.

https://doi.org/10.1182/blood-2018-99-114316

Published: 2018

Journal Articles

IL-32γ Induces M2 Macrophage Polarization with Enhanced Ability of Macrophage-Mediated Drug Resistance in Myeloma Cells through STAT3 and NF-κB Activation

Haimeng Yan, Xuanru Lin, MD, Xi Huang, MD, Zhang En Fan, Donghua He, Xu Ruyi, Huiyao Gu, Yi Li, MD, Jingsong He, MD, Qing Yi, MD PhD, Zhen Cai, MD PhD

Blood (2017) 130 (Supplement 1): 1781.

https://doi.org/10.1182/blood.V130.Suppl_1.1781.1781

Published: 2017

Journal Articles

Interactions Between BAFF and BAFF Receptors Are Involved in Macrophage-Induced Bortezomib Resistance in Myeloma

Jing Chen, M.MD, Donghua He, PhD, Xing Guo, M.MD, Qingxiao Chen, M.MD, Xuanru Lin, M.MD, Jingsong He, Xi Huang, M.MD, Haimeng Yan, Yi Li, PhD, Li Yang, PhD, Yang Yang, PhD, Enfan Zhang, M.MD, He Huang, MD PhD, Zhen Cai, MD PhD

Blood (2016) 128 (22): 4429.

https://doi.org/10.1182/blood.V128.22.4429.4429

Published: 2016

Journal Articles

Interference of HMGB1 Lead to Increased Vulnerability of MM Cells to Dexamethasone and Doxorubicin

Xing Guo, M.MD, Donghua He, PhD, Jing Chen, M.MD, Xuanru Lin, M.MD, Qingxiao Chen, M.MD, Haimeng Yan, Xi Huang, M.MD, Yi Li, PhD, Li Yang, PhD, Enfan Zhang, M.MD, Yang Yang, PhD, Wenjun Wu, MD, Jingsong He, He Huang, MD PhD, Zhen Cai, MD PhD

Blood (2016) 128 (22): 2086.

https://doi.org/10.1182/blood.V128.22.2086.2086

Published: 2016

Journal Articles

Quercetin Displays Anti-Myeloma Activity and Synergistic Effect with Dexamethasone in Vitro and In Vivo Xenograft Models

Xing Guo, M.MD, Donghua He, PhD, Li Yang, PhD, Yi Li, PhD, Qingxiao Chen, M.MD, Jing Chen, M.MD, Enfan Zhang, M.MD, Xuanru Lin, M.MD, Jingsong He, PhD, Yang Yang, PhD, Xiaoyan Han, MD, Gaofeng Zheng, MD, Wenjun Wu, MD, Yi Zhao, PhD, He Huang, MD PhD, Zhen Cai, MD PhD

Blood (2015) 126 (23): 5339.

https://doi.org/10.1182/blood.V126.23.5339.5339

Published: 2015

Journal Articles

Efficacy and Safety of Bortezomib Based Regimens Retreatment in Relapsed Multiple Myeloma Patients: Results from a Retrospective Study.

Wenjun Wu, MD, Gaofeng Zheng, MD, Xiaoyan Han, MD, Yi Zhao, PhD, Donghua He, PhD, Yang Yang, PhD, Jingsong He, PhD, Weiyan Zheng, Jie Sun, MD PhD, Jimin Shi, Guoqing Wei, MD PhD, He Huang, MD PhD, Zhen Cai

Blood (2015) 126 (23): 5387.

https://doi.org/10.1182/blood.V126.23.5387.5387

Published: 2015

Journal Articles

TET2 Downregulation Leads to AML Cells Sensitive to Decitabine

Qingxiao Chen, M.MD, Jingsong He, PhD, Xing Guo, M.MD, Jing Chen, M.MD, Li Yang, PhD, Xuanru Lin, M.MD, Yi Li, PhD, Enfan Zhang, M.MD, Yang Yang, PhD, Wenjun Wu, MD, Donghua He, PhD, He Huang, MD PhD, Shizhou Liu, MD PhD, Zhen Cai, MD PhD

Blood (2015) 126 (23): 3643.

https://doi.org/10.1182/blood.V126.23.3643.3643

Published: 2015

Journal Articles

The Role BAFF and BAFF Receptors in Macrophage Induced Drug Resistance of Multiple Myeloma

Jing Chen, M.MD, Donghua He, PhD, Xing Guo, M.MD, Li Yang, M.MD, Yi Li, M.MD, Qingxiao Chen, M.MD, Jingsong He, Yang Yang, PhD, Enfan Zhang, M.MD, WenJun Wu, Xiaoyan Han, M.MD, Gaofeng Zheng, M.MD, Yi Zhao, PhD, He Huang, MDPhD, Zhen Cai, MDPhD

Blood (2014) 124 (21): 5701.

https://doi.org/10.1182/blood.V124.21.5701.5701

Published: 2014

NARROW

Survival of Hemodialysis-Dependent Multiple Myeloma Patients and Factors Associated with Dialysis Independence: A Real-World Study in China

Selinexor Combined with Daratumumab, Thalidomide, and Dexamethasone in Patients with First Relapsed Multiple Myeloma: A Single-Arm, Multicenter, Prospective Study

The Efficacy of Roxadustat in Multiple Myeloma Patients with Renal Insufficiency and Anemia: A Real-World Study

Increase of Dnts Correlated with Clinic Outcome after Allogeneic DNT Cells Infusion in r/r AML Patients

Real-World Clinical Outcomes of Pomalidomide-Based and Daratumumab-Based Therapies in Patients with Relapsed/Refractory Multiple Myeloma: A Single-Center Retrospective Cohort Study

Preliminary Outcomes of Orelabrutinib Plus R-CHOP in Treatment-Naive Patients with Double-Expression Diffuse Large B-Cell Lymphoma

A Prospective Phase II Clinical Study of Low-Frequency Daratumumab for the Treatment of Systemic Light Chain Amyloidosis

When Patients with Plasma Cell Disorders Encountered the Largest Omicron Wave (December 2022) in China: A Real-World Multicenter and Multiregional Study

Analysis of Clinical Characteristics and High-Risk Factors of Patients with Extramedullary Relapse Multiple Myeloma

The Efficacy of Residual Plerixafor of Second-Day Stem Cell Mobilization in Multiple Myeloma Patients

Preliminary Outcomes of Orelabrutinib Plus RCHOP in Treatment-Naïve Patients with Double-Expression Diffuse Large B Cell Lymphoma

Efficacy and Safety of Chidamide Combined with Thalidomide, Cyclophosphamide, and Dexamethasone (TC2D) As a Novel Oral Quadruplet Regimen for the Treatment of Relapsed/Refractory Multiple Myeloma: Initial Results of a Phase IIa, Multicenter Clinical Trial

Multiple Myeloma Cell-Derived Interleukin-32gamma Increases the Immunosuppressive Function of Macrophages By Promoting Indoleamine 2,3-Dioxygenase (IDO) Expression

IL-32γ Induces M2 Macrophage Polarization with Enhanced Ability of Macrophage-Mediated Drug Resistance in Myeloma Cells through STAT3 and NF-κB Activation

Interactions Between BAFF and BAFF Receptors Are Involved in Macrophage-Induced Bortezomib Resistance in Myeloma

Interference of HMGB1 Lead to Increased Vulnerability of MM Cells to Dexamethasone and Doxorubicin

Quercetin Displays Anti-Myeloma Activity and Synergistic Effect with Dexamethasone in Vitro and In Vivo Xenograft Models

Efficacy and Safety of Bortezomib Based Regimens Retreatment in Relapsed Multiple Myeloma Patients: Results from a Retrospective Study.

TET2 Downregulation Leads to AML Cells Sensitive to Decitabine

The Role BAFF and BAFF Receptors in Macrophage Induced Drug Resistance of Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only